Subject: Glucose Monitoring (Continuous, Interstitial Fluid)*

Effective Date: September 11, 2007

Department(s): Utilization Management

Policy: Continuous glucose monitoring in the interstitial fluid with an implanted or non-implanted sensor, in diabetics, is reimbursable under Plans administered by QualCare, Inc. under the conditions outlined in this Policy.

Objective: To assure proper and consistent reimbursement and to delineate criteria for coverage of a medically necessary diabetes supply.

Procedure: I. For initial requests, documentation must be received from a physician that includes the following:

   A. The patient has type 1 diabetes (ICD-9 250.0 – 250.9 ICD-10 E10.1-E10.9).
   B. Glycemic control is inadequate despite compliance with self-monitoring of blood glucose and administration of insulin.
   C. Insulin injections are administered ≥3 times per day or the patient is using an insulin pump.
   D. Fingersticks are being performed ≥4 times per day.
   E. Hemoglobin A1c is >7%; or if ≤7%, there are severe hypoglycemic episodes, nocturnal hypoglycemia, or hypoglycemic episodes of which the patient is unaware.
   F. Relevant codes are HCPCS A9276 – A9279, S1030, S1031, and CPT 95250, 95251.

II. For replacement requests, documentation must be received from a physician that includes both of the following:
• The monitor or component is malfunctioning, is no longer under warranty and cannot be repaired.
• A clinical evaluation within the previous sixth months by the physician including a recommendation for continued use of a continuous glucose monitor.

The following devices or products are not covered as they have not been demonstrated to improve health outcomes and are therefore not medically necessary:

• Remote glucose monitoring (ie my Sentry)
• Diabetes management software for downloading and/or analyzing blood glucose monitoring results

References


Standards of Medical Care in Diabetes-2012. American Diabetes Association. Diabetes Care 2012;25(S1):s11-s63


Eisenbarth GS. Update in Type 1 Diabetes. J Clin Endocrinol Metab 2007;92(7):2403-2407 (Jul)


*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.